Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RP59500 therapy.
Launay
O
O
Service de Médecine Interne, Hôpital Bichat-Claude Bernard, Paris, France.
Chemlal
K
K
Andrieu
V
V
Carbon
C
C
D000743:Anemia, Hemolytic / Q000097:blood / Q000139:chemically induced* / Q000150:complications; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D010019:Osteomyelitis / Q000097:blood / Q000150:complications / Q000188:drug therapy; D012156:Reticulocytes; D013203:Staphylococcal Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy; D014769:Virginiamycin / Q000009:adverse effects* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C062940:quinupristin-dalfopristin